Skip to main content

Advertisement

Log in

Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission

  • Letter to the Editor
  • Published:
Medical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Inaba K et al. Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer. Med Oncol; 2011. doi:10.1007/s12032-011-9893-0.

  2. Huober J, Schoch O, Templeton A, Spirig C, Thürlimann B. Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer. Chemotherapy. 2010;56(1):69–70.

    Article  PubMed  CAS  Google Scholar 

  3. Mirza MR, et al. A phaseII study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin. Gynecol Oncol. 2010;119(1):26–31.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael Mark.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mark, M., Thürlimann, B. Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission. Med Oncol 29, 1477–1478 (2012). https://doi.org/10.1007/s12032-011-0002-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-0002-1

Keywords

Navigation